Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × Lamivudine × Clear all

Phase

Phase 4 1 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Virus Diseases 1 Recurrence 1 Lymphoma 1

Interventions

Dexamethasone 27 Cyclophosphamide 23 venetoclax 18 Lenalidomide 14 Bortezomib 13 fludarabine 12 pembrolizumab 11 Cytarabine 11 Carboplatin 11 Calcium Dobesilate 10 Rituximab 9 pomalidomide 8 fludarabine phosphate 7 Nivolumab 7 Gemcitabine 7 Azacitidine 7 carfilzomib 6 blinatumomab 6 Bendamustine Hydrochloride 6 selinexor 5 obinutuzumab 5 ibrutinib 5 daratumumab 5 Temozolomide 5 Decitabine 5 Cisplatin 5 elotuzumab 4 Methotrexate 4 Etoposide 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06494579 2025-12-16

Lamivudine for Solid Tumors

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡